Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Decreases By 34.3%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a significant decrease in short interest in February. As of February 15th, there was short interest totalling 13,800 shares, a decrease of 34.3% from the January 31st total of 21,000 shares. Based on an average trading volume of 373,100 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.5% of the company’s shares are short sold.

Coeptis Therapeutics Stock Up 2.8 %

Shares of Coeptis Therapeutics stock opened at $10.75 on Friday. Coeptis Therapeutics has a 1 year low of $2.31 and a 1 year high of $13.70. The business has a 50-day moving average of $9.27 and a two-hundred day moving average of $5.75. The company has a market capitalization of $34.85 million, a P/E ratio of -1.85 and a beta of -0.82. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.40 and a quick ratio of 0.40.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.